DE

Dnyaneshwar Eknath Pathare

Active Director Director DIN 08662425
DIN 08662425 First appointment Jan 2020 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Dnyaneshwar Eknath Pathare

Data last updated:

Dnyaneshwar Eknath Pathare is a Director at Medeasy Pharma Private Limited (since 2020). The company operates in Chemicals.

DIN 08662425
Primary Designation Director
Industry Chemicals
First Appointment 08 Jan 2020
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Medeasy Pharma Private Limited U24230PN2020PTC188966
Director08 Jan 20202020Active

Board colleagues of Dnyaneshwar Eknath Pathare

Directorship timeline

Open interactive timeline →
Medeasy Pharma Private Limited
Premium access

Shareholding and investment profile for Dnyaneshwar Eknath Pathare

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dnyaneshwar Eknath Pathare

Dnyaneshwar Eknath Pathare currently holds 1 directorship: Medeasy Pharma Private Limited (Director, since 08 Jan 2020).

Dnyaneshwar Eknath Pathare was first appointed on 08 Jan 2020 as Director at Medeasy Pharma Private Limited.

The current boards of Dnyaneshwar Eknath Pathare's companies include Abhishek Shyam Wai (Medeasy Pharma Private Limited), Ramesh Shivram Satpute (Medeasy Pharma Private Limited), Vikram Ramesh Satpute (Medeasy Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available